JP7662337B2 - 前立腺癌の検出および治療方法 - Google Patents

前立腺癌の検出および治療方法 Download PDF

Info

Publication number
JP7662337B2
JP7662337B2 JP2020544261A JP2020544261A JP7662337B2 JP 7662337 B2 JP7662337 B2 JP 7662337B2 JP 2020544261 A JP2020544261 A JP 2020544261A JP 2020544261 A JP2020544261 A JP 2020544261A JP 7662337 B2 JP7662337 B2 JP 7662337B2
Authority
JP
Japan
Prior art keywords
tmprss2
score
prostate cancer
expression levels
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514624A (ja
JP2021514624A5 (enExample
Inventor
マーク モドリン アービン
キッド マーク
ドロズドフ イグナット
Original Assignee
リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー filed Critical リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー
Publication of JP2021514624A publication Critical patent/JP2021514624A/ja
Publication of JP2021514624A5 publication Critical patent/JP2021514624A5/ja
Priority to JP2025061707A priority Critical patent/JP2025096376A/ja
Application granted granted Critical
Publication of JP7662337B2 publication Critical patent/JP7662337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020544261A 2018-02-22 2019-02-21 前立腺癌の検出および治療方法 Active JP7662337B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061707A JP2025096376A (ja) 2018-02-22 2025-04-03 前立腺癌の検出および治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
US62/633,675 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061707A Division JP2025096376A (ja) 2018-02-22 2025-04-03 前立腺癌の検出および治療方法

Publications (3)

Publication Number Publication Date
JP2021514624A JP2021514624A (ja) 2021-06-17
JP2021514624A5 JP2021514624A5 (enExample) 2022-02-28
JP7662337B2 true JP7662337B2 (ja) 2025-04-15

Family

ID=65686083

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544261A Active JP7662337B2 (ja) 2018-02-22 2019-02-21 前立腺癌の検出および治療方法
JP2025061707A Pending JP2025096376A (ja) 2018-02-22 2025-04-03 前立腺癌の検出および治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061707A Pending JP2025096376A (ja) 2018-02-22 2025-04-03 前立腺癌の検出および治療方法

Country Status (15)

Country Link
US (3) US11410748B2 (enExample)
EP (2) EP4538393A3 (enExample)
JP (2) JP7662337B2 (enExample)
KR (2) KR20260018206A (enExample)
CN (2) CN112673115B (enExample)
AU (2) AU2019224025B2 (enExample)
BR (1) BR112020016989A2 (enExample)
CA (1) CA3091647A1 (enExample)
DK (1) DK3755816T3 (enExample)
ES (1) ES3023842T3 (enExample)
IL (1) IL276748A (enExample)
MX (2) MX2020008702A (enExample)
PL (1) PL3755816T3 (enExample)
SG (1) SG11202007922XA (enExample)
WO (1) WO2019165021A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
US20230049979A1 (en) * 2020-02-06 2023-02-16 OncoHost Ltd. Machine learning prediction of therapy response
IL310769A (en) 2021-08-11 2024-04-01 Oncohost Ltd Predicting patient response
US20230326554A1 (en) * 2022-04-08 2023-10-12 Rutgers, The State University Of New Jersey Identifying treatment response signatures
WO2024081796A1 (en) 2022-10-12 2024-04-18 Liquid Biopsy Research LLC Methods for prostate cancer detection in saliva
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
KR102891032B1 (ko) * 2022-12-29 2025-12-03 재단법인대구경북과학기술원 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用
CN119964650B (zh) * 2024-12-24 2025-09-30 深圳大学 一种基于集成学习的基因调控网络推断方法和系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140249041A1 (en) 2009-05-27 2014-09-04 Region Midtjylland Marker of Prostate Cancer
JP2015511814A (ja) 2012-01-31 2015-04-23 ジェノミック ヘルス， インコーポレイテッド 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP2016526922A (ja) 2013-08-06 2016-09-08 エクソサム ダイアグノスティクス，インコーポレイティド 尿バイオマーカーコホート、遺伝子発現特性、およびその使用の方法
WO2017149106A1 (en) 2016-03-04 2017-09-08 Ait Austrian Institute Of Technology Gmbh Prostate cancer diagnostic method and means

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656140A1 (en) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CA3081061C (en) * 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
WO2014012176A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer
EP2882869A4 (en) * 2012-08-07 2016-04-20 Jackson H M Found Military Med PROSTATE CANCER GENE EXPRESSION PROFILE
MY182773A (en) * 2012-11-20 2021-02-05 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
CN105209636A (zh) * 2013-03-15 2015-12-30 麦塔马克基因股份有限公司 用于癌症预后的组合物和方法
CN105658810B (zh) * 2013-06-13 2020-08-21 南澳大学 用于检测前列腺癌的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140249041A1 (en) 2009-05-27 2014-09-04 Region Midtjylland Marker of Prostate Cancer
JP2015511814A (ja) 2012-01-31 2015-04-23 ジェノミック ヘルス， インコーポレイテッド 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP2016526922A (ja) 2013-08-06 2016-09-08 エクソサム ダイアグノスティクス，インコーポレイティド 尿バイオマーカーコホート、遺伝子発現特性、およびその使用の方法
WO2017149106A1 (en) 2016-03-04 2017-09-08 Ait Austrian Institute Of Technology Gmbh Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
AU2025238057A1 (en) 2025-11-27
SG11202007922XA (en) 2020-09-29
AU2019224025B2 (en) 2025-06-26
US20190259471A1 (en) 2019-08-22
JP2021514624A (ja) 2021-06-17
IL276748A (en) 2020-10-29
US20230298695A1 (en) 2023-09-21
DK3755816T3 (da) 2025-04-28
KR102921718B1 (ko) 2026-02-03
KR20260018206A (ko) 2026-02-06
ES3023842T3 (en) 2025-06-03
US20260066046A1 (en) 2026-03-05
AU2019224025A1 (en) 2020-09-10
US11410748B2 (en) 2022-08-09
WO2019165021A1 (en) 2019-08-29
PL3755816T3 (pl) 2025-06-30
JP2025096376A (ja) 2025-06-26
MX2020008702A (es) 2020-09-25
CA3091647A1 (en) 2019-08-29
MX2025000449A (es) 2025-03-07
CN119932188A (zh) 2025-05-06
BR112020016989A2 (pt) 2020-12-29
EP3755816A1 (en) 2020-12-30
CN112673115B (zh) 2025-02-18
EP4538393A3 (en) 2025-07-02
KR20200123450A (ko) 2020-10-29
CN112673115A (zh) 2021-04-16
EP3755816B1 (en) 2025-02-12
EP4538393A2 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
JP2025096376A (ja) 前立腺癌の検出および治療方法
US12305240B2 (en) Methods for colon cancer detection and treatment
JP7724265B2 (ja) 遺伝子発現アッセイを使った予測ペプチド受容体放射性核種療法
HK40043345B (en) Methods for prostate cancer detection and treatment
HK40043345A (en) Methods for prostate cancer detection and treatment
HK40042084B (en) Methods for colon cancer detection and treatment monitoring
HK40042084A (en) Methods for colon cancer detection and treatment monitoring
CN114428174A (zh) 一种胃癌预后生物标志物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250403

R150 Certificate of patent or registration of utility model

Ref document number: 7662337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150